Author

P. C. Fridy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 3 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:differential expression· 1 Research Focus:protein folding & dynamics· 1 Assay:protein structure· 1 Assay:structural biology· 1

Frequent Co-Authors

B. T. Chait· 4 shared a. Sali· 3 shared M. P. Rout· 3 shared N. E. Ketaren· 3 shared T. Sanyal· 3 shared F. D. Mast· 2 shared J. P. Olivier· 2 shared K. R. Molloy· 2 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBiochemistry

B. T. Chait

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Unique Binding and Stabilization Mechanisms Employed By and Engineered Into Nanobodies.

N. E. Ketaren, P. C. Fridy, V. Malashkevich, T. Sanyal, M. Brilliantes, M. K. Thompson, D. A. Orens, J. B. Bonanno, a. Sali, S. C. Almo, B. T. Chait, M. P. Rout

This study identifies mechanisms enabling nanobodies to bind antigens with high affinity and stability, revealing a conserved region critical for their function and suggesting strategies for their optimization.

bioRxiv · Oct 22, 2023 · PreprintBiochemistry

Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus

N. E. Ketaren, F. D. Mast, P. C. Fridy, J. P. Olivier, T. Sanyal, A. Sali, B. T. Chait, M. P. Rout, J. Aitchison

The paper shows that nanobodies against ancestral SARS-CoV-2 spike protein remain effective against recent variants, including omicron sublineages and emerging XBB/BQ.1.1 variants.

bioRxiv · Jul 14, 2023Biochemistry

Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker

M. S. Taylor, W. Connie, P. C. Fridy, S. J. Zhang, Y. Senussi, J. C. Wolters, W.-C. Cheng, J. Heaps, B. D. Miller, K. Mori, L. Cohen, H. Jiang, K. R. Molloy, B. L. Norden, B. T. Chait, , O. H. Yilmaz

This study develops ultrasensitive assays to detect ORF1p in plasma, showing its potential as a multi-cancer biomarker for early detection and monitoring.

bioRxiv · Jan 25, 2023 · PreprintCancer Biology

Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2

F. D. Mast, P. C. Fridy, N. E. Ketaren, J. Wang, E. Y. Jacobs, J. P. Olivier, T. Sanyal, K. R. Molloy, F. Schmidt, M. Rutkowska, Y. Weisblum, L. M. Rich, E. R. Vanderwall, N. Dambrauskas, V. Vigdorovich, , M. P. Rout

This paper presents a large repertoire of high-affinity nanobodies against SARS-CoV-2 Spike protein with potent neutralization properties and resistance to viral variants.

bioRxiv · Apr 8, 2021Biochemistry